Literature DB >> 23800385

[Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].

József Maléth1, Péter Hegyi.   

Abstract

Proton pump inhibitors are widely used in the treatment of acid-related diseases because they are considered to be effective and safe. In the past 10 years the use of proton pump inhibitors increased by over three folds, which is not associated with the increased prevalence of acid-related diseases obviously. However, like any other drugs, they have potential side effects. In recent years many studies have been published about the correlation between long-term proton pump inhibitor therapy and the increase of bone fractures. Most studies showed that long-term proton pump inhibitor therapy moderately increased fracture risk. The underlying mechanisms of increased number of bone fractures are not clarified yet. However, chronic acid suppression caused by long-term proton pump inhibitor therapy may play a crucial role in decreased absorption of calcium and vitamin B12 and, therefore, indirectly affecting the bones resulting in a decrease of bone mineral density. The available data suggest that proton pump inhibitors should be used with caution in patients with increased risk of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23800385     DOI: 10.1556/OH.2013.29656

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  2 in total

1.  Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics.

Authors:  Mária Matuz; Ria Benkő; Zsófia Engi; Krisztina Schváb; Péter Doró; Réka Viola; Mária Szabó; Gyöngyvér Soós
Journal:  Front Pharmacol       Date:  2020-09-08       Impact factor: 5.810

2.  Association between Benign Paroxysmal Positional Vertigo and Previous Proton Pump Inhibitor Use: A Nested Case-Control Study Using a National Health Screening Cohort.

Authors:  So Young Kim; Dae Myoung Yoo; Mi Jung Kwon; Ji Hee Kim; Joo-Hee Kim; Joong Seob Lee; Hyo Geun Choi
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.